USD 152.36
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | -1.6 | -1.6 | -4.9 | -8.9 | 3.1 | -4.1 | -4.4 | 11.1 | 41.4 | 68106.6 |
| S&P 500 | 0.0 | 0.8 | 5.6 | 9.4 | 14.5 | 32.4 | 33.3 | 95.6 | 191.7 | 34157.5 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | JNJ |
| name | Johnson & Johnson |
| price | 152.36 |
| changes percentage | -1.58 |
| change | -2.44 |
| day low | 152.31 |
| day high | 154.80 |
| year high | 168.85 |
| year low | 143.13 |
| market cap | 366824983200 |
| price avg 50 | 159.13 |
| price avg 200 | 155.80 |
| exchange | NYSE |
| volume | 5592026 |
| avg volume | 6455787 |
| open | 154.80 |
| previous close | 154.80 |
| eps | 6.05 |
| pe | 25.18 |
| earnings announcement | 2025-01-22T13:30:00.000+0000 |
| shares outstanding | 2407620000 |
| timestamp | 2024-12-03 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000200406 | |||
| revenue | 85159000000 | 79990000000 | 6.46 |
| gross profit | 58606000000 | 55394000000 | 5.80 |
| gross profit ratio | 0.69 | 0.69 | -0.62 |
| research and development expenses | 15048000000 | 14135000000 | 6.46 |
| operating expenses | 35564000000 | 33181000000 | 7.18 |
| interest income | 1261000000 | 490000000 | 157.35 |
| interest expense | 772000000 | 276000000 | 179.71 |
| ebitda | 23725000000 | 27170000000 | -12.68 |
| ebitdaratio | 0.28 | 0.38 | -26.12 |
| operating income | 23409000000 | 23193000000 | 0.93 |
| operating income ratio | 0.27 | 0.29 | -5.20 |
| net income | 35153000000 | 17941000000 | 95.94 |
| net income ratio | 0.41 | 0.22 | 84.04 |
| eps | 13.88 | 6.86 | 102.33 |
Revenue Growth: revenue increased to 85,159 million in 2023 from 79,990 million in 2022 representing a change of 6.46%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 58,606 million in 2023 from 55,394 million in 2022 representing a change of 5.8%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 15,048 million in 2023 from 14,135 million in 2022 representing a change of 6.46%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Income: Operating income increased to 23,409 million in 2023 from 23,193 million in 2022 representing a change of 0.93%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 35,153 million in 2023 from 17,941 million in 2022 representing a change of 95.94%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 13.88 in 2023 from 13.88 in 2022 representing a change of 102.33%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 35,564 million in 2023 from 33,181 million in 2022 representing a change of 7.18%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 23,725 million in 2023 from 27,170 million in 2022 representing a change of -12.68%. The decrease in EBITDA indicates declined operational efficiency and profitability.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000200406 | |||
| revenue | 22471000000 | 22447000000 | 0.11 |
| gross profit | 15508000000 | 15578000000 | -0.45 |
| gross profit ratio | 0.69 | 0.69 | -0.56 |
| research and development expenses | 4952000000 | 3440000000 | 43.95 |
| operating expenses | 10427000000 | 8921000000 | 16.88 |
| interest income | 292000000 | 395000000 | -26.08 |
| interest expense | 193000000 | 270000000 | -28.52 |
| ebitda | 5484000000 | 8476000000 | -35.30 |
| ebitdaratio | 0.24 | 0.41 | -40.97 |
| operating income | 2694000000 | 7499000000 | -64.08 |
| operating income ratio | 0.12 | 0.33 | -64.11 |
| net income | 2694000000 | 4686000000 | -42.51 |
| net income ratio | 0.12 | 0.21 | -42.57 |
| eps | 1.12 | 1.95 | -42.56 |
Revenue Growth: revenue increased to 22,471 million in 2024Q3 from 22,447 million in 2024Q2 representing a change of 0.11%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 4,952 million in 2024Q3 from 3,440 million in 2024Q2 representing a change of 43.95%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 10,427 million in 2024Q3 from 8,921 million in 2024Q2 representing a change of 16.88%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Gross Profit: Gross Profit decreased to 15,508 million in 2024Q3 from 15,578 million in 2024Q2 representing a change of -0.45%. This indicates a sales profitability decline, which is a negative sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 5,484 million in 2024Q3 from 8,476 million in 2024Q2 representing a change of -35.3%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to 2,694 million in 2024Q3 from 7,499 million in 2024Q2 representing a change of -64.08%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 2,694 million in 2024Q3 from 4,686 million in 2024Q2 representing a change of -42.51%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 1.12 in 2024Q3 from 1.12 in 2024Q2 representing a change of -42.56%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000200406 | |||
| total assets | 167558000000 | 187378000000 | -10.58 |
| total liabilities | 98784000000 | 110574000000 | -10.66 |
| total equity | 68774000000 | 76804000000 | -10.46 |
| cash and cash equivalents | 21859000000 | 12889000000 | 69.59 |
| short term investments | 1068000000 | 9392000000 | -88.63 |
| long term investments | 0 | 0 | NaN |
| total current assets | 53495000000 | 55294000000 | -3.25 |
| total non current assets | 114063000000 | 132084000000 | -13.64 |
| total current liabilities | 46282000000 | 55802000000 | -17.06 |
| total non current liabilities | 52502000000 | 54772000000 | -4.14 |
| common stock | 3120000000 | 3120000000 | 0.00 |
| retained earnings | 153843000000 | 128345000000 | 19.87 |
| total debt | 29332000000 | 39642000000 | -26.01 |
Total Assets: Total Assets decreased to 167,558 million in 2023 from 187,378 million in 2022 representing a change of -10.58%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 68,774 million in 2023 from 76,804 million in 2022 representing a change of -10.46%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 1,068 million in 2023 from 9,392 million in 2022 representing a change of -88.63%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 53,495 million in 2023 from 55,294 million in 2022 representing a change of -3.25%. This indicates a worsen liquidity position.
Total Liabilities: Total Liabilities decreased to 98,784 million in 2023 from 110,574 million in 2022 representing a change of -10.66%. This indicates a decrease in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 21,859 million in 2023 from 12,889 million in 2022 representing a change of 69.59%. This indicates an increase in available liquid assets.
Total Current Liabilities: Total Current Liabilities decreased to 46,282 million in 2023 from 55,802 million in 2022 representing a change of -17.06%. This indicates a lower short-term debt burden.
Retained Earnings: Retained Earnings increased to 153,843 million in 2023 from 128,345 million in 2022 representing a change of 19.87%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 29,332 million in 2023 from 39,642 million in 2022 representing a change of -26.01%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000200406 | |||
| total assets | 178287000000 | 181088000000 | -1.55 |
| total liabilities | 108129000000 | 109550000000 | -1.30 |
| total equity | 70158000000 | 71538000000 | -1.93 |
| cash and cash equivalents | 19980000000 | 24878000000 | -19.69 |
| short term investments | 317000000 | 597000000 | -46.90 |
| long term investments | 0 | 1143000000 | -100.00 |
| total current assets | 53249000000 | 57817000000 | -7.90 |
| total non current assets | 125038000000 | 123271000000 | 1.43 |
| total current liabilities | 51759000000 | 53933000000 | -4.03 |
| total non current liabilities | 56370000000 | 55617000000 | 1.35 |
| common stock | 3120000000 | 3120000000 | 0.00 |
| retained earnings | 155179000000 | 155360000000 | -0.12 |
| total debt | 35751000000 | 41491000000 | -13.83 |
Total Assets: Total Assets decreased to 178,287 million in 2024Q3 from 181,088 million in 2024Q2 representing a change of -1.55%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 70,158 million in 2024Q3 from 71,538 million in 2024Q2 representing a change of -1.93%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 19,980 million in 2024Q3 from 24,878 million in 2024Q2 representing a change of -19.69%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 317 million in 2024Q3 from 597 million in 2024Q2 representing a change of -46.9%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 53,249 million in 2024Q3 from 57,817 million in 2024Q2 representing a change of -7.9%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to 155,179 million in 2024Q3 from 155,360 million in 2024Q2 representing a change of -0.12%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 108,129 million in 2024Q3 from 109,550 million in 2024Q2 representing a change of -1.3%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 51,759 million in 2024Q3 from 53,933 million in 2024Q2 representing a change of -4.03%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 35,751 million in 2024Q3 from 41,491 million in 2024Q2 representing a change of -13.83%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000200406 | |||
| net change in cash | 7732000000 | -360000000 | 2,247.78 |
| operating cash flow | 22791000000 | 21194000000 | 7.54 |
| free cash flow | 18248000000 | 17185000000 | 6.19 |
| capital expenditure | -4543000000 | -4009000000 | -13.32 |
| depreciation and amortization | 7486000000 | 6970000000 | 7.40 |
| deferred income tax | -4194000000 | -1663000000 | -152.19 |
| stock based compensation | 1162000000 | 1138000000 | 2.11 |
| accounts payables | 2346000000 | 1098000000 | 113.66 |
| inventory | -1323000000 | -2527000000 | 47.65 |
| acquisitions net | 0 | -17652000000 | 100.00 |
| investments in property plant and equipment | -4543000000 | -4009000000 | -13.32 |
| net cash used for investing activites | 878000000 | -12371000000 | 107.10 |
| debt repayment | -2734000000 | -2132000000 | -28.24 |
| common stock issued | 4241000000 | 0 | NaN |
| common stock repurchased | -5054000000 | -6035000000 | 16.26 |
| dividends paid | -11770000000 | -11682000000 | -0.75 |
| net cash used provided by financing activities | -15825000000 | -8871000000 | -78.39 |
| cash at end of period | 21859000000 | 14127000000 | 54.73 |
| accounts receivables | -624000000 | -1290000000 | 51.63 |
| cash at beginning of period | 14127000000 | 14487000000 | -2.48 |
Net Change in Cash: Net Change in Cash increased to 7,732 million in 2023 from -360 million in 2022 representing a change of 2247.78%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 22,791 million in 2023 from 21,194 million in 2022 representing a change of 7.54%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 18,248 million in 2023 from 17,185 million in 2022 representing a change of 6.19%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -4,543 million in 2023 from -4,009 million in 2022 representing a change of -13.32%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation increased to 1,162 million in 2023 from 1,138 million in 2022 representing a change of 2.11%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 2,346 million in 2023 from 1,098 million in 2022 representing a change of 113.66%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to -624 in 2023 from -1,290 million in 2022 representing a change of 51.63%. This suggests that the company is less capable of collecting payments from its customers.
Dividends Paid: Dividends Paid decreased to -11,770 million in 2023 from -11,682 million in 2022 representing a change of -0.75%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000200406 | |||
| operating cash flow | 7993000000 | 5633000000 | 41.90 |
| free cash flow | 5714000000 | 4657000000 | 22.70 |
| capital expenditure | -2279000000 | -976000000 | -133.50 |
| depreciation and amortization | 1846000000 | 1782000000 | 3.59 |
| deferred income tax | 90000000 | -695000000 | 112.95 |
| stock based compensation | 295000000 | 341000000 | -13.49 |
| accounts receivables | -96000000 | -884000000 | 89.14 |
| accounts payables | 0 | 2932000000 | -100.00 |
| inventory | -299000000 | -391000000 | 23.53 |
| acquisitions net | -338000000 | -12633000000 | 97.32 |
| investments in property plant and equipment | -1836000000 | -976000000 | -88.11 |
| net cash used for investing activites | -3128000000 | -13687000000 | 77.15 |
| debt repayment | -7401000000 | 11543000000 | -164.12 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | -539000000 | -136000000 | -296.32 |
| dividends paid | -2985000000 | -2985000000 | 0.00 |
| net cash used provided by financing activities | -9882000000 | 7544000000 | -230.99 |
| net change in cash | -4898000000 | -595000000 | -723.19 |
| cash at end of period | 19980000000 | 24878000000 | -19.69 |
| cash at beginning of period | 24878000000 | 25473000000 | -2.34 |
Net Change in Cash: Net Change in Cash decreased to -4,898 million in 2024Q3 from -595 million in 2024Q2 representing a change of -723.19%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Deferred Income Tax: Deferred Income Tax increased to 90 million in 2024Q3 from -695 million in 2024Q2 representing a change of 112.95%. This indicates that the company's tax liability for future periods has increased.
Accounts Receivables: Accounts Receivables increased to -96 in 2024Q3 from -884 million in 2024Q2 representing a change of 89.14%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to 7,993 million in 2024Q3 from 5,633 million in 2024Q2 representing a change of 41.9%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 5,714 million in 2024Q3 from 4,657 million in 2024Q2 representing a change of 22.7%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -2,279 million in 2024Q3 from -976 million in 2024Q2 representing a change of -133.5%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 295 million in 2024Q3 from 341 million in 2024Q2 representing a change of -13.49%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2024Q3 from 2,932 million in 2024Q2 representing a change of -100.0%. This indicates that the company has reduced its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2023-01-01 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 33.61 | 30.61 | 9.83 |
| net income per share | 13.88 | 6.86 | 102.13 |
| operating cash flow per share | 9.0 | 8.11 | 10.93 |
| free cash flow per share | 7.2 | 6.58 | 9.54 |
| cash per share | 9.05 | 8.53 | 6.15 |
| book value per share | 27.15 | 29.39 | -7.62 |
| tangible book value per share | -0.77 | 0.87 | -189.11 |
| shareholders equity per share | 27.15 | 29.39 | -7.62 |
| interest debt per share | 11.88 | 15.27 | -22.20 |
| market cap | 397100790000 | 461691910050 | -13.99 |
| enterprise value | 404573790000 | 488444910050 | -17.17 |
| pe ratio | 11.3 | 25.73 | -56.10 |
| price to sales ratio | 4.66 | 5.77 | -19.21 |
| pocfratio | 17.42 | 21.78 | -20.02 |
| pfcf ratio | 21.76 | 26.87 | -19.00 |
| pb ratio | 5.77 | 6.01 | -3.95 |
| ptb ratio | 5.77 | 6.01 | -3.95 |
| ev to sales | 4.75 | 6.11 | -22.20 |
| enterprise value over ebitda | 17.05 | 17.98 | -5.14 |
| ev to operating cash flow | 17.75 | 23.05 | -22.98 |
| ev to free cash flow | 22.17 | 28.42 | -22.00 |
| earnings yield | 0.09 | 0.04 | 127.81 |
| free cash flow yield | 0.05 | 0.04 | 23.46 |
| debt to equity | 0.43 | 0.52 | -17.37 |
| debt to assets | 0.18 | 0.21 | -17.26 |
| net debt to ebitda | 0.31 | 0.98 | -68.01 |
| current ratio | 1.16 | 0.99 | 16.65 |
| interest coverage | 30.32 | 84.03 | -63.92 |
| income quality | 1.71 | 1.18 | 44.78 |
| dividend yield | 0.03 | 0.03 | 17.14 |
| payout ratio | 0.33 | 0.65 | -48.58 |
| sales general and administrative to revenue | 0.24 | 0.24 | -0.81 |
| research and ddevelopement to revenue | 0.18 | 0.18 | -0.00 |
| intangibles to total assets | 0.42 | 0.4 | 6.12 |
| capex to operating cash flow | 0.2 | 0.19 | 5.38 |
| capex to revenue | 0.05 | 0.05 | 6.44 |
| capex to depreciation | 0.61 | 0.58 | 5.51 |
| stock based compensation to revenue | 0.01 | 0.01 | -4.09 |
| graham number | 92.06 | 67.37 | 36.65 |
| roic | 0.21 | 0.17 | 25.34 |
| return on tangible assets | 0.36 | 0.16 | 128.35 |
| graham net net | -23.33 | -27.79 | 16.04 |
| working capital | 7213000000 | -508000000 | 1,519.88 |
| tangible asset value | -1959000000 | 2268000000 | -186.38 |
| net current asset value | -45289000000 | -55280000000 | 18.07 |
| invested capital | 97844000000 | 92010000000 | 6.34 |
| average receivables | 14456000000 | 14661000000 | -1.40 |
| average payables | 9760500000 | 10472000000 | -6.79 |
| average inventory | 10724500000 | 10327500000 | 3.84 |
| days sales outstanding | 63.75 | 64.06 | -0.49 |
| days payables outstanding | 132.4 | 146.75 | -9.78 |
| days of inventory on hand | 153.7 | 152.38 | 0.87 |
| receivables turnover | 5.73 | 5.7 | 0.49 |
| payables turnover | 2.76 | 2.49 | 10.84 |
| inventory turnover | 2.37 | 2.4 | -0.86 |
| roe | 0.51 | 0.23 | 118.81 |
| capex per share | 1.79 | 1.53 | 16.90 |
ROE: Return on Equity (ROE) increased to 0.51 on 2023-12-31 from 0.23 on 2023-01-01, representing a change of 118.81%. Suggesting the company has been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 1.16 on 2023-12-31 from 0.99 on 2023-01-01, representing a change of 16.65%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.43 on 2023-12-31 from 0.52 on 2023-01-01, representing a change of -17.37%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 11.30 on 2023-12-31 from 25.73 on 2023-01-01, representing a change of -56.10%. Indicating a decrease in the relative valuation of the company's stock.
| 2024-09-29 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| JNJ | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 9.33 | 9.33 | 0.09 |
| net income per share | 1.12 | 1.95 | -42.52 |
| operating cash flow per share | 3.32 | 2.34 | 41.87 |
| free cash flow per share | 2.37 | 1.93 | 22.67 |
| cash per share | 8.43 | 10.58 | -20.34 |
| book value per share | 29.14 | 29.72 | -1.95 |
| tangible book value per share | -5.87 | -5.17 | -13.60 |
| shareholders equity per share | 29.14 | 29.72 | -1.95 |
| interest debt per share | 14.93 | 17.35 | -13.95 |
| market cap | 390126713880 | 352451792000 | 10.69 |
| enterprise value | 405897713880 | 369064792000 | 9.98 |
| pe ratio | 36.2 | 18.8 | 92.54 |
| price to sales ratio | 17.36 | 15.7 | 10.57 |
| pocfratio | 48.81 | 62.57 | -21.99 |
| pfcf ratio | 68.28 | 75.68 | -9.79 |
| pb ratio | 5.56 | 4.93 | 12.87 |
| ptb ratio | 5.56 | 4.93 | 12.87 |
| ev to sales | 18.06 | 16.44 | 9.86 |
| enterprise value over ebitda | 74.01 | 43.54 | 69.98 |
| ev to operating cash flow | 50.78 | 65.52 | -22.49 |
| ev to free cash flow | 71.04 | 79.25 | -10.36 |
| earnings yield | 0.01 | 0.01 | -48.06 |
| free cash flow yield | 0.01 | 0.01 | 10.85 |
| debt to equity | 0.51 | 0.58 | -12.14 |
| debt to assets | 0.2 | 0.23 | -12.48 |
| net debt to ebitda | 2.88 | 1.96 | 46.73 |
| current ratio | 1.03 | 1.07 | -4.03 |
| interest coverage | 13.96 | 27.77 | -49.74 |
| income quality | 2.97 | 1.2 | 146.82 |
| dividend yield | 0.01 | 0.01 | -9.66 |
| payout ratio | 1.11 | 0.64 | 73.94 |
| sales general and administrative to revenue | 0 | 0.24 | -100.00 |
| research and ddevelopement to revenue | 0.22 | 0.15 | 43.80 |
| intangibles to total assets | 0.47 | 0.46 | 1.95 |
| capex to operating cash flow | 0.29 | 0.17 | 64.56 |
| capex to revenue | 0.1 | 0.04 | 133.25 |
| capex to depreciation | 1.23 | 0.55 | 125.41 |
| stock based compensation to revenue | 0.01 | 0.02 | -13.58 |
| graham number | 27.09 | 36.08 | -24.93 |
| roic | 0.02 | 0.05 | -62.04 |
| return on tangible assets | 0.03 | 0.05 | -40.60 |
| graham net net | -28.83 | -27.48 | -4.90 |
| working capital | 1490000000 | 3884000000 | -61.64 |
| tangible asset value | -14131000000 | -12437000000 | -13.62 |
| net current asset value | -54880000000 | -51733000000 | -6.08 |
| invested capital | 106258000000 | 107607000000 | -1.25 |
| average receivables | 15984000000 | 15370000000 | 3.99 |
| average payables | 8901000000 | 8511000000 | 4.58 |
| average inventory | 12386000000 | 11776000000 | 5.18 |
| days sales outstanding | 64.78 | 63.33 | 2.30 |
| days payables outstanding | 115.73 | 115.93 | -0.17 |
| days of inventory on hand | 162.9 | 159.44 | 2.17 |
| receivables turnover | 1.39 | 1.42 | -2.25 |
| payables turnover | 0.78 | 0.78 | 0.17 |
| inventory turnover | 0.55 | 0.56 | -2.12 |
| roe | 0.04 | 0.07 | -41.38 |
| capex per share | 0.95 | 0.41 | 133.46 |
ROE: Return on Equity (ROE) decreased to 0.04 on 2024-09-29 Q3 from 0.07 on 2024-06-30 Q2, representing a change of -41.38%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 36.20 on 2024-09-29 Q3 from 18.80 on 2024-06-30 Q2, representing a change of 92.54%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.51 on 2024-09-29 Q3 from 0.58 on 2024-06-30 Q2, representing a change of -12.14%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 1.03 on 2024-09-29 Q3 from 1.07 on 2024-06-30 Q2, representing a change of -4.03%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Positive Sentiment: Discounted Cash Flow value is 171.64 which is higher than current price 152.36, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-12-03 10:01:42
Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.
Sentiment: Positive
Publish Date: 2024-12-02 14:30:44
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Sentiment: Positive
Publish Date: 2024-12-02 08:00:00
Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis SPRING HOUSE, Pa. , Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis (PsO) and children 5 years of age and older with active juvenile psoriatic arthritis (jPsA).a The PsO submission is based on data from the Phase 3 PROTOSTAR study in pediatric patients with moderate to severe plaque PsO and bridging pharmacokinetic (PK) data from the Phase 3 VOYAGE 1 and 2 studies in adult patients with moderate to severe plaque PsO.
Sentiment: Positive
Publish Date: 2024-12-02 07:00:00
BRIDGEWATER, N.J. and BENGALURU, India , Dec. 2, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA) has approved YESINTEK™ (Ustekinumab-kfce), a biosimilar to the reference product, Stelara® (Ustekinumab).
Sentiment: Positive
Publish Date: 2024-12-01 05:52:00
You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.
Sentiment: Positive
Publish Date: 2024-11-29 07:30:00
Big Tech dominates markets but faces risks like slowing growth, AI dependency, and inflated valuations. Dividend stalwarts offer a safer, smarter alternative. Dividend stocks, like those in VYM and SCHD ETFs, have matched or beat tech returns since 2021, fueled by strong cash flow, low risks, and reliable growth. By focusing on dividend stalwarts, investors can achieve long-term growth, income, and stability—outperforming tech-heavy portfolios over time.
Sentiment: Positive
Publish Date: 2024-11-28 15:00:00
Johnson & Johnson offers investors an effective combination of dividend income and dividend growth, evidenced by its Dividend Yield [TTM] of 3.13% and 5-Year Dividend Growth Rate [CAGR] of 5.61%. The company from the Pharmaceuticals Industry, which has an Aaa credit rating from Moody's, can serve as a strategically important core-position within your dividend portfolio. Allocating the largest proportion of your dividend portfolio to Johnson & Johnson can position your portfolio for reduced volatility and help to decrease its overall risk level.
Sentiment: Positive
Publish Date: 2024-11-27 05:00:06
Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forward expected earnings (2025), versus 14.7x for JNJ.
Sentiment: Positive
Publish Date: 2024-11-26 18:00:00
I added shares of the Schwab U.S. Dividend Equity ETF and the Cohen & Steers Quality Income Realty Fund to The Dividend Income Accelerator Portfolio, boosting income and portfolio diversification. The Schwab U.S. Dividend Equity ETF now represents 21.22% of our dividend portfolio, enhancing the portfolio's risk-reward profile. Cohen & Steers Quality Income Realty Fund, now 8.70% of our dividend portfolio, elevates the portfolio's dividend income capacity and Real Estate Sector allocation, improving diversification.
Sentiment: Positive
Publish Date: 2024-11-26 06:18:00
Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.
Sentiment: Positive
Publish Date: 2024-11-25 11:46:53
Key Points Donald Trump's victory is positive for the stock market.
Sentiment: Positive
Publish Date: 2024-11-25 10:10:27
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
Sentiment: Negative
Publish Date: 2024-11-23 07:20:00
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.
Sentiment: Negative
Publish Date: 2024-11-23 05:36:00
2 Unstoppable Dividend Stocks to Buy Now With $500
Sentiment: Neutral
Publish Date: 2024-11-23 04:02:00
2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade
Sentiment: Positive
Publish Date: 2024-11-22 08:00:00
Following recent U.S. FDA approval of TREMFYA® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that offers choice of subcutaneous or intravenous induction in UC Submission is supported by the Phase 3 ASTRO study, which achieved the primary endpoint of clinical remission at Week 12 and met all secondary endpoints in adults with moderately to severely active UC SPRING HOUSE, Pa. , Nov. 22, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a subcutaneous (SC) induction regimen of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active UC.
Sentiment: Positive
Publish Date: 2024-11-22 07:15:00
Dividend Kings, like Coca-Cola, Johnson & Johnson, and Walmart, are prime long-term investments due to their consistent dividend growth over 50+ years. Coca-Cola offers a 3% yield and strong EBITDA growth, making it a solid buy despite recent stock volatility and health-related headwinds. Johnson & Johnson, despite legal issues, remains undervalued with a 3.2% yield and robust free cash flow, making it an attractive investment.
Sentiment: Positive
Publish Date: 2024-11-21 08:00:00
Given its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expected earnings.
Sentiment: Positive
Publish Date: 2024-11-20 16:05:25
AT&T, Altria Group, and Energy Transfer are top buys with dividends from $1K invested exceeding single share prices, meeting the dogcatcher ideal. Analysts forecast 15.47% to 28.33% net gains by November 2025 for top-ten F500IL dogs, with Energy Transfer as the standout “safer” choice. Eight F500IL stocks show negative free cash flow margins, making them unsafe buys; price drops or dividend increases could make top-yield F500IL fair-priced.
Sentiment: Positive
Publish Date: 2024-11-20 16:00:17
The decline in J&J's share price and the drug/biotech sector's downturn in the past month have left investors wondering if they should sell J&J stock.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
